title: Peripheral hemodynamic and humoral effects of oral zofenopril calcium (SQ. 26,991) in patients with congestive heart failure.
abstract: In 14 patients with congestive heart failure (CHF) of various grade (NYHA class 2-4) the effects of zofenopril calcium (SQ 26,991) on blood pressure and forearm circulation were studied by venous occlusion plethysmography. Changes in plasma renin activity (PRA), aldosterone, Atrial natriuretic factor (ANF) and arginine-vasopressin (AVP) were also measured. Two hours after oral administration of 7.5 mg of zofenopril we observed a decrease in blood pressure, heart rate, and forearm vascular resistance along with an increase in venous distensibility. Zofenopril also decreased ANP levels in a manner directly related to peripheral venodilatation (r = .64; P less than .05) and modified arginine-vasopressin (AVP) proportionally to the fall in blood pressure observed in response to drug administration (%SBP/%AVP: r = .64, P less than .05; %DBP/%AVP: r = .67, P less than .05). Hemodynamic and humoral responses to zofenopril occurred without any significant unwanted adverse reaction, even in patients with greater pressor reduction. We conclude that oral acute zofenopril administration, in patients with congestive heart failure, causes an arterial and venous forearm vasodilatation which is probably involved in the acute changes in plasma levels of ANF and AVP observed after drug administration.
authors.affiliation: Department of Clinical Pharmacology and Therapeutics, University of Bologna, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Borghi
authors.forename: C
authors.initials: C
authors.lastname: Magelli
authors.forename: S
authors.initials: S
authors.lastname: Boschi
authors.forename: F V
authors.initials: FV
authors.lastname: Costa
authors.forename: M
authors.initials: M
authors.lastname: Capelli
authors.forename: E
authors.initials: E
authors.lastname: Varani
authors.forename: B
authors.initials: B
authors.lastname: Magnani
authors.forename: E
authors.initials: E
authors.lastname: Ambrosioni
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000803:Angiotensin I / Q000097:blood; D001127:Arginine Vasopressin / Q000097:blood; D009320:Atrial Natriuretic Factor / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects; D002216:Captopril / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D005260:Female; D005542:Forearm / Q000098:blood supply; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D012083:Renin / Q000097:blood; D014664:Vasodilation / Q000187:drug effects; D014680:Veins / Q000187:drug effects
chemical_list: D001127:Arginine Vasopressin; C044958:zofenopril; D009320:Atrial Natriuretic Factor; D000803:Angiotensin I; D002216:Captopril; D012083:Renin